Jump to content

CX3C motif chemokine receptor 1

From Wikipedia, the free encyclopedia
(Redirected from CX3CR1 (gene))
CX3CR1
Identifiers
AliasesCX3CR1, CCRL1, CMKBRL1, CMKDR1, GPR13, GPRV28, V28, C-X3-C motif chemokine receptor 1
External IDsOMIM: 601470; MGI: 1333815; HomoloGene: 20350; GeneCards: CX3CR1; OMA:CX3CR1 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

1524

13051

Ensembl

ENSG00000168329

ENSMUSG00000052336

UniProt

P49238

Q9Z0D9

RefSeq (mRNA)

NM_001337
NM_001171171
NM_001171172
NM_001171174

NM_009987

RefSeq (protein)

NP_001164642
NP_001164643
NP_001164645
NP_001328

NP_034117

Location (UCSC)Chr 3: 39.26 – 39.28 MbChr 9: 119.73 – 119.9 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

CX3C motif chemokine receptor 1 (CX3CR1), also known as the fractalkine receptor or G-protein coupled receptor 13 (GPR13), is a transmembrane protein of the G protein-coupled receptor 1 (GPCR1) family and the only known member of the CX3C chemokine receptor subfamily.[5][6][7]

As the name suggests, this receptor binds the inflammatory chemokine CX3CL1 (also called neurotactin in mice or fractalkine in humans). This endogenous ligand solely binds to CX3CR1 receptor. Interaction of CX3CR1 with CX3CL1 can mediate migration, adhesion and retention of leukocytes, because Fractalkine exists as membrane-anchored protein (mCX3CL1) as well as cleaved soluble molecule (sCX3CL1) due to proteolysis by metalloproteinases (MPPs). The shedded form carries out typical function of conventional chemokines, the chemotaxis, while the membrane-bound protein behaves as adhesion molecule for facilitation of diapedesis.[7][8]

Both partners of CX3CL1-CX3CR1 axis are present on numerous cell types from hematopoietic and nonhematopoietic cells throughout the body. Moreover, their distinct cell expression is dependent on specific tissues and organs, which provides broad sphere of biological activity. Hence, considering their various functional activity, they are also linked with multiple neurodegenerative and inflammatory disorders as well as with tumorigenesis.[7][8][9]

Genetics

[edit]

The coding gene for CX3CR1 is now officially called identically to its protein: CX3CR1 gene,[5][6] but may be still referred to by other older names such as V28; CCRL1; GPR13; CMKDR1; GPRV28; CMKBRL1. A genome location of the gene in humans is on the short arm of the chromosome 3p22.2. It is composed of four exons (only one contains coding region) and three intronic elements. Expression of the genomic sequence is regulated via three promoters.[10][11]

Two missense mutations in CX3CR1 gene, variants of single nucleotide polymorphism (SNP) of the receptor, are responsible for functional change of the protein. Names of these variants are derived from given substitution and its position: valine to isoleucine (V249I) and threonine to methionine (T280M). Polymorphism of CX3CR1 has been linked to diseases relating to cardiovascular system (e.g. Atherosclerosis), nervous system (e.g. Alzheimer's disease, Sclerosis) or infections (e.g. systemic candidiasis.[12][13][14]

Orthologs of CX3CR1 gene are found among animals, especially in mammals with high functional similarity, namely chimpanzee, dog, cat, mouse and rat. Orthologs are located on chromosome 9qF4 in the mouse genome and in the rat 8th chromosome on position 8q32.[15][16]

Expression

[edit]

CX3CR1 is expressed constitutively or in inflammatory response in various cells from hematopoietic lineage: T lymphocytes, natural killer (NK) cells, dendritic cells, B lymphocytes, mast cells, monocytes, macrophages, neutrophils, microglia, osteoclasts and thrombocytes. Furthermore, this receptor can be also found in nonhematopoietic tissues such as endothelial cells, epithelial cells, myocytes and astrocytes. Considering the CX3CR1 abundance in the body, it was also found to be expressed by some types of malignant cells.[9][10][12][17]

Function

[edit]

The CX3CR1 receptor is part of the G-protein chemokine receptor family with the metabotropic function. Its intracellular signalling cascades are responsible for modulating cell activity rather towards higher active state as in survival, migration and proliferation.[7][18]

In the recognition of immune cells during inflammation, the function of CX3CL1-CX3CR1 axis in the bloodstream is mainly recruitment of immune cells by migration through chemotaxis and diapedesis. Of course, as a part of the inflammatory immune response against pathogens this role considered as protective. However, as with most immune cells and proteins, in inflammatory or autoimmune diseases, CX3CR1 signalling is associated with some disease's pathophysiology.[7]

Expression of this receptor appears to be associated with lymphocytes.[19] CX3CR1 is also expressed by monocytes and plays a major role in the survival of monocytes.[20] Communication in blood vessels through the CX3CL1-CX3CR1 axis between endothelial cells and monocytes is responsible for formation of extracellular matrix and angiogenesis. It has been shown that CX3CR1 can influence monocytes already in bone marrow by means of retention and release. Moreover in bone marrow, CX3CR1 influences bone remodeling through role in differentiation of osteoclasts and osteoblasts.[9]

The CX3CL1/CX3CR1 axis role in the nervous system is to mediate communication between microglia, neuroglia and neurons for regulation of microglia activity, hence this axis plays a neurodegenerative and neuroprotective function based on the physiological state.[7][9]

Fractalkine signaling has also recently been discovered to play a developmental role in the migration of microglia in the central nervous system to their synaptic targets, where phagocytosis and synaptic refinement occur. CX3CR1 knockout mice had more synapses on hippocampal neurons than wild-type mice.[21]

Structure

[edit]

CX3CR1 is integral membrane protein formed by 355 amino acids with molecular weight around 40 kDa, which consist of three distinguishable segments: extracellular, transmembrane and intracellular part.[7][8] As a member of the biggest class of GPCR family the rhodopsin-like receptors, the intracellular part of receptor, C-terminus of the polypeptide and three intracellular loops, is a bounding place with conserved DRYLAIV motif for the heterotrimeric G protein. This family is also known as T-transmembrane receptors (7-TM) by reason of 7 α-helices of transmembrane protein, which are alternately located in the cell's cytoplasmic membrane.[12][16] Extracellular side of CX3CR1 consists of N-terminus of the polypeptide chain and three extracellular loops, forming a binding place for its main ligand CX3CL1, but also CCL26 (Eotaxin-3): has lower binding affinity when compared to fractalkine), immunoglobulins or infectious agents.[9][10]

Signalling cascade

[edit]

CX3CL1-CX3CR1 axis' signalling commences via activation of the receptor by its agonist's binding. It is followed by conformational change and component's dissociation of the heterotrimeric G complex, which consists of three subunits: α (alpha), β (beta) and γ (gamma). Several important signalling pathways are triggered by separated parts of G protein (Gα and Gβγ) such as the PLC/PKC pathway, the PI3K/AKT/NFκB pathway, the Ras/Raf/MEK/ERK (MAPK) pathway (or p38 and JNK) and the CREB pathway. All of those signalling cascades are responsible for diverse cellular behaviours and regulations, in terms of increased proliferation, survival and cell growth, metabolic regulation, induction of migration, apoptosis resistance and secretion of hormones and inflammatory cytokines. Products of CX3CR1 signalling cascades possess importance in the immune response of CX3CR1 positive hematopoietic cells.[9][10][18]

Clinical significance

[edit]

CX3CR1 and immune cells are strongly connected due to its abundant cell surface expression. Therefore, clinical meaning of CX3CR1 can be found in diseases connected with immunity. CX3CR1 is able to increase accumulation of immune cells in the affected body part, which results in disease aggravation. Few examples: allergies, Rheumatoid arthritis, Renal diseases, Chronic liver disease or Crohn's disease.[10][18][22]

CX3CR1 is also a coreceptor for HIV-1, and some variations in this gene lead to increased susceptibility to HIV-1 infection and rapid progression to AIDS.[23]

Since CX3CR1 plays a major role for interaction between endothelial cells and immune cells, it can aid vascular build up on the artery walls (plaque), thus it has been associated with Atherosclerosis. In addition, this may lead to thrombosis, other cardiovascular diseases or even cerebral ischemia.[10][18][17]

CX3CL1-CX3CR1 axis has an ability to control neurological inflammation through activation of microglia. Its role in brain pathologies can be therefore protective but also detrimental. There are connections between microglia and neurodegenerative disorders like Alzheimer's disease, Parkinson's disease or even with neurocognitive HIV-dementia.[10][24] Moreover, CX3CR1 variants have been described to modify the survival time and the progression rate of patients with amyotrophic lateral sclerosis.[25]

Mutations in CX3CR1 are associated to dysplasia of the hip.[26] Homozygous CX3CR1-M280 mutation impairs human monocyte survival and deteriorates outcome of human systemic candiasis.[27]

As mentioned before, this receptor and its ligand are important for the metabolism of the bone tissue in terms of differentiation of osteoclasts and osteoblasts. Overactivation of osteoclasts as well as accumulation of other immune cells has been linked to Osteoporosis.[9][17][8]

CX3CR1 with Fractalkine have a meaningful place also in many various types of cancer (e.g. Neuroblastoma, Prostate cancer, Gastric adenocarcinoma or B cell lymphomas) where CX3CL1-CX3CR1 axis is a double agent, providing antitumoral effects (stimulating and recruiting immune cells to target neoplasm) and protumoral effects (stimulating important activity in malignant cells like: invasion, proliferation and apoptosis resistance, for facilitating metastasis). Therefore, it has a lot of potential as therapeutical target in cancer.[9][10][18]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000168329 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000052336 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b Combadiere C, Ahuja SK, Murphy PM (August 1995). "Cloning, chromosomal localization, and RNA expression of a human beta chemokine receptor-like gene". DNA and Cell Biology. 14 (8): 673–680. doi:10.1089/dna.1995.14.673. PMID 7646814.
  6. ^ a b Combadiere C, Salzwedel K, Smith ED, Tiffany HL, Berger EA, Murphy PM (September 1998). "Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1". The Journal of Biological Chemistry. 273 (37): 23799–23804. doi:10.1074/jbc.273.37.23799. PMID 9726990.
  7. ^ a b c d e f g Ferretti E, Pistoia V, Corcione A (2014). "Role of fractalkine/CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies". Mediators of Inflammation. 2014: 480941. doi:10.1155/2014/480941. PMC 3985314. PMID 24799766.
  8. ^ a b c d Wojdasiewicz P, Turczyn P, Dobies-Krzesniak B, Frasunska J, Tarnacka B (2019-11-12). "Role of CX3CL1/CX3CR1 Signaling Axis Activity in Osteoporosis". Mediators of Inflammation. 2019: 7570452. doi:10.1155/2019/7570452. PMC 6875359. PMID 31780870.
  9. ^ a b c d e f g h Lee M, Lee Y, Song J, Lee J, Chang SY (February 2018). "Tissue-specific Role of CX3CR1 Expressing Immune Cells and Their Relationships with Human Disease". Immune Network. 18 (1): e5. doi:10.4110/in.2018.18.e5. PMC 5833124. PMID 29503738.
  10. ^ a b c d e f g h Rivas-Fuentes S, Salgado-Aguayo A, Arratia-Quijada J, Gorocica-Rosete P (2021). "Regulation and biological functions of the CX3CL1-CX3CR1 axis and its relevance in solid cancer: A mini-review". Journal of Cancer. 12 (2): 571–583. doi:10.7150/jca.47022. PMC 7738983. PMID 33391453.
  11. ^ DeVries ME, Cao H, Wang J, Xu L, Kelvin AA, Ran L, et al. (April 2003). "Genomic organization and evolution of the CX3CR1/CCR8 chemokine receptor locus". The Journal of Biological Chemistry. 278 (14): 11985–11994. doi:10.1074/jbc.M211422200. PMID 12551893.
  12. ^ a b c Chamera K, Szuster-Głuszczak M, Basta-Kaim A (August 2021). "Shedding light on the role of CX3CR1 in the pathogenesis of schizophrenia". Pharmacological Reports. 73 (4): 1063–1078. doi:10.1007/s43440-021-00269-5. PMC 8413165. PMID 34021899.
  13. ^ Sakai M, Takeuchi H, Yu Z, Kikuchi Y, Ono C, Takahashi Y, et al. (June 2018). "Polymorphisms in the microglial marker molecule CX3CR1 affect the blood volume of the human brain". Psychiatry and Clinical Neurosciences. 72 (6): 409–422. doi:10.1111/pcn.12649. PMID 29485193. S2CID 4777950.
  14. ^ Wu J, Yin RX, Lin QZ, Guo T, Shi GY, Sun JQ, et al. (2014). "Two polymorphisms in the Fractalkine receptor CX3CR1 gene influence the development of atherosclerosis: a meta-analysis". Disease Markers. 2014: 913678. doi:10.1155/2014/913678. PMC 4158466. PMID 25221380.
  15. ^ "CX3CR1 Gene - GeneCards | CX3C1 Protein | CX3C1 Antibody". www.genecards.org. Archived from the original on 2022-06-19. Retrieved 2022-09-08.
  16. ^ a b Poniatowski ŁA, Wojdasiewicz P, Krawczyk M, Szukiewicz D, Gasik R, Kubaszewski Ł, Kurkowska-Jastrzębska I (April 2017). "Analysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents". Molecular Neurobiology. 54 (3): 2167–2188. doi:10.1007/s12035-016-9787-4. PMC 5355526. PMID 26927660.
  17. ^ a b c Imai T, Yasuda N (December 2016). "Therapeutic intervention of inflammatory/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway". Inflammation and Regeneration. 36 (1): 9. doi:10.1186/s41232-016-0017-2. PMC 5725656. PMID 29259682.
  18. ^ a b c d e Pap R, Montskó G, Jánosa G, Sipos K, Kovács GL, Pandur E (April 2020). "Fractalkine Regulates HEC-1A/JEG-3 Interaction by Influencing the Expression of Implantation-Related Genes in an In Vitro Co-Culture Model". International Journal of Molecular Sciences. 21 (9): 3175. doi:10.3390/ijms21093175. PMC 7246682. PMID 32365902.
  19. ^ Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, et al. (November 1997). "Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion". Cell. 91 (4): 521–530. doi:10.1016/S0092-8674(00)80438-9. PMID 9390561. S2CID 17281691.
  20. ^ Landsman L, Bar-On L, Zernecke A, Kim KW, Krauthgamer R, Shagdarsuren E, et al. (January 2009). "CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival". Blood. 113 (4): 963–972. doi:10.1182/blood-2008-07-170787. PMID 18971423.
  21. ^ Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, et al. (September 2011). "Synaptic pruning by microglia is necessary for normal brain development". Science. 333 (6048): 1456–1458. Bibcode:2011Sci...333.1456P. doi:10.1126/science.1202529. PMID 21778362. S2CID 12883061.
  22. ^ von Vietinghoff S, Kurts C (August 2021). "Regulation and function of CX3CR1 and its ligand CX3CL1 in kidney disease". Cell and Tissue Research. 385 (2): 335–344. doi:10.1007/s00441-021-03473-0. PMC 8523406. PMID 34009468.
  23. ^ "Entrez Gene: chemokine (C-X3-C motif) receptor 1". Archived from the original on 2022-09-08. Retrieved 2017-10-29.
  24. ^ Pawelec P, Ziemka-Nalecz M, Sypecka J, Zalewska T (October 2020). "The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders". Cells. 9 (10): 2277. doi:10.3390/cells9102277. PMC 7600611. PMID 33065974.
  25. ^ Lopez-Lopez A, Gamez J, Syriani E, Morales M, Salvado M, Rodríguez MJ, et al. (7 May 2014). "CX3CR1 is a modifying gene of survival and progression in amyotrophic lateral sclerosis". PLOS ONE. 9 (5): e96528. Bibcode:2014PLoSO...996528L. doi:10.1371/journal.pone.0096528. PMC 4013026. PMID 24806473.
  26. ^ Feldman GJ, Parvizi J, Sawan H, Erickson JA, Peters CL (September 2014). "Linkage mapping and whole exome sequencing identify a shared variant in CX3CR1 in a large multi-generation family". The Journal of Arthroplasty. 29 (9 Suppl): 238–241. doi:10.1016/j.arth.2014.05.014. PMID 24998320.
  27. ^ Collar AL, Swamydas M, O'Hayre M, Sajib MS, Hoffman KW, Singh SP, et al. (February 2018). "The homozygous CX3CR1-M280 mutation impairs human monocyte survival". JCI Insight. 3 (3). doi:10.1172/jci.insight.95417. PMC 5821174. PMID 29415879.

Further reading

[edit]
[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Retrieved from "https://wiki.riteme.site/w/index.php?title=CX3C_motif_chemokine_receptor_1&oldid=1254895059"